Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting
Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting
Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced a poster presentation and an oral presentation by partner company, Avistone Biotechnology, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31-June 4, 2024, in Chicago, Ill. and virtually. Copies of the poster and oral presentation are available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations.
Apollomics股份有限公司（纳斯达克股票代码：APLM）（“Apollomics”或“公司”），是一家临床前期生物制药公司，开发多个肿瘤药物候选品，以治疗难以治疗和耐药的癌症，宣布伴侣公司Avistone生物技术将在2024年美国临床肿瘤学会（ASCO）年度会议上进行海报报告和口头报告，该会议将于2024年5月31日至6月4日在伊利诺伊州芝加哥举行。海报和口头报告的副本可在Apollomics网站的ir.apollomicsinc.com/news-events/presentations上获取。